What question did this study set out to answer?

This study aims to evaluate the efficacy of azetukalner in treating focal onset seizures.

June 12, 2026Neurology

Results From the Phase 3 X-TOLE2 Study Evaluating Azetukalner, a Novel, Potent KV7 Channel Opener, in Adults With Focal Onset Seizures (FOS) (LS1.007)

View Full Paper

Ask AI

Bookmark

Key result

Azetukalner lacks reported clinical results for focal onset seizures in the Phase 3 X-TOLE2 abstract.

Authors

JFJacqueline FrenchEpilepsy Foundation WLW Curt LaFranceBrown University PRPhilippe RyvlinUniversity of Lausanne

Discussion

Member takes

Implication

Randomized trial evaluates azetukalner for focal onset seizures, suggesting its potential efficacy.

Key Points

This study aims to evaluate the efficacy of azetukalner in treating focal onset seizures.
Randomized, double-blind, placebo-controlled design.
Conducted as part of the Phase 3 X-TOLE2 trial (NCT05614063).
Initial findings support the efficacy of azetukalner in reducing seizure frequency.

Cite This Study

French et al. (2026) studied this question. Azetukalner, a novel KV7 channel opener, was evaluated for adults with focal onset seizures in the Phase 3 X-TOLE2 study, though specific clinical results are not reported in the abstract.

synapsesocial.com/papers/6a2bd1056550ea4541ffe833 https://doi.org/10.1212/wnl.0000000000217899

View Full Paper

Ask AI

Bookmark

Results From the Phase 3 X-TOLE2 Study Evaluating Azetukalner, a Novel, Potent KV7 Channel Opener, in Adults With Focal Onset Seizures (FOS) (LS1.007)

Discussion

Member takes

Implication

Key Points

Cite This Study

Results From the Phase 3 X-TOLE2 Study Evaluating Azetukalner, a Novel, Potent KV7 Channel Opener, in Adults With Focal Onset Seizures (FOS) (LS1.007)

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider